At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 129 enrolled
Drug / intervention
Evolocumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
In Brief
A Phase 3 clinical trial evaluating Evolocumab and Placebo for Subjects With Hyperlipidemia, Dyslipidemia. Completed, enrolled 129 participants across 15 sites in 3 countries.
Detailed Summary
A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Netherlands, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartApr 2016
Primary CompletionApr 2018
TodayJul 2026
First PostedApr 6, 2016
Enrollment StartApr 14, 2016
Primary CompletionApr 5, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.2 years ago
Interventions
Evolocumabdrug
Administered subcutaneously once a month using an autoinjector/pen.
Placebodrug
Administered subcutaneously once a month using an autoinjector/pen.